Background
==========

Chronic fatigue syndrome (CFS) is a debilitating illness that causes substantial reduction in previous levels of professional, recreational, social, or educational activities \[[@B1]\]. CFS presents a challenge for patients, health care providers, and health insurance groups because of its incapacitating nature, unknown cause, and poorly understood clinical course. A systematic review \[[@B2]\] of prospective studies found that 0%-37% (median = 6%) of adult CFS patients recovered, and 6%-63% (median = 35%) improved over time. Patients who recovered or improved were younger, did not have a co-morbid psychiatric disorder, and did not believe that the illness was due to a physical cause. More recent estimates of recovery and improvement are similar \[[@B3]-[@B6]\] (Table 1 \[see [Additional file: 1](#S1){ref-type="supplementary-material"}\]). Short duration predicted a higher likelihood of recovery among patients enrolled in a surveillance system \[[@B4]\] but was not associated with recovery in severely ill patients selected from a CFS clinic \[[@B5]\] or from a CFS research registry \[[@B6]\]. All of these studies were conducted in clinical settings and thus involved people who were sick enough and had sufficient resources to seek and obtain medical care. In addition, most of the studies involved patients from specialty clinics at tertiary care medical centers who have been triaged or whose diagnosis was continuously supported by the health care system.

The objective of our study was to characterize the clinical course of CFS in the general population. We identified and followed CFS subjects from Wichita, Kansas for up to 3 years. We evaluated changes in CFS classification, case-defining criteria \[[@B1]\], wellness scores, hours of activities and sleep, and treatment use. We also determined associations between these changes and demographic and clinical factors.

Methods
=======

Design
------

This study adhered to human experimentation guidelines of the U.S. Department of Health and Human Services. All participants were volunteers who gave informed consent. In 1997, we conducted a random-digit-dialing survey to estimate the prevalence of CFS and other fatiguing illnesses in Wichita, Kansas \[[@B7]\]. Briefly, a screening telephone survey asked 56,154 residents the following question: \"Are you currently suffering from severe fatigue, extreme tiredness, or exhaustion that has been present for a period of one month or longer?\" A total of 3,528 fatigued and 3,654 non-fatigued subjects were asked to participate in a detailed telephone interview to assess CFS case-defining criteria and other characteristics. Persons fatigued for ≥ 6 months, not feeling better after rest, not reporting any fatigue-associated medical or psychiatric conditions, and reporting at least 4 of the 8 CFS symptoms were eligible to participate in a clinical evaluation. These individuals were mailed a self-administered questionnaire requesting additional information about fatigue, symptoms, and medical history. During the clinic visit, subjects had a standardized physical examination and laboratory tests of blood and urine samples administered, and were given the Diagnostic Interview Scheduling (DIS) for DSM-IV \[[@B8]\] to establish psychiatric diagnoses. A physician review committee evaluated the clinical data and classified subjects on the basis of 1994 CFS case-definition criteria \[[@B1]\] as having medical or psychiatric diagnoses that could explain fatigue (permanent exclusions), temporary medical conditions that required resolution prior to classification (e.g., abnormal laboratory results, pregnancy), insufficient fatigue severity or number of symptoms, or CFS. Subjects who did not have any permanent medical or psychiatric exclusion \[[@B7]\] were re-interviewed yearly (4,228 in 1998, 3,980 in 1999, and 3,474 in 2000). Newly eligible subjects were invited for an initial evaluation, and subjects who had previously come to the clinic were invited for a follow-up visit. The physician review committee again assessed CFS classification.

This study considered CFS subjects who were identified during any year of the study and who had at least one follow-up visit. Of note, none of the participants in the study were informed of their CFS classification.

Changes in CFS classification
-----------------------------

Changes in CFS classification at follow-up occurred because case-defining criteria were no longer satisfied (i.e., subjects reporting absence of fatigue, less than 4 of 8 symptoms, rest made fatigue a lot better, or fatigue did not interfere a lot with work, educational, social/recreational, or personal activities). Identification of alternative diagnoses (permanent or temporary) also precluded CFS classification.

Total remission was defined as having none of the case-defining criteria (i.e., absence of fatigue, less than 4 symptoms, health did not interfere with activities). Partial remission was defined as having some but not all of the case-defining criteria. Total (partial) sustained remission was defined as having two consecutive follow-up visits with total (partial) remission.

Fatigue reduction between clinic visits
---------------------------------------

Although subjects might not have been in remission at the follow-up clinic visit, they might have experienced at least one episode of reduced fatigue between clinic visits. Subjects at follow-up were asked \"Since your last clinic visit, has there ever been a time when you have felt less fatigued?\" Subjects reporting reduced fatigue were queried as to how long the most recent episode had lasted, whether they used any treatment since their previous clinic visit, and whether they thought the treatment was responsible for reducing their fatigue. Subjects who did not report reduced fatigue were not asked questions about treatment use.

Fatigue Assessment Instrument
-----------------------------

Fatigued subjects also completed the 29-item Fatigue Assessment Instrument \[[@B9]\] and scores were calculated for four fatigue subscales: overall fatigue severity, situation-specific fatigue (measuring fatigue sensitivity to particular circumstances, such as heat, cold, and stress), fatigue consequences (measuring loss of patience, motivation or ability to concentrate), and fatigue responsiveness to rest or sleep.

Wellness scores, hours spent on activities and sleep during the past month
--------------------------------------------------------------------------

Subjects were asked the following questions referring to their wellness and activities during the past month: \"Where would you place yourself in terms of energy, wellness, and ability to complete your every day activities on a scale from 1 to 100?\"; \"On average, how many hours per week did you spend on work duties, including working from home and travel related to work; household chores, such as cleaning, grocery shopping, and caring for your family; activities such as hobbies, schooling, or volunteer work?\"; \"How many hours of sleep, per day, including naps, have you averaged during weekdays and on the weekends?\".

Statistical analyses
--------------------

χ^2^, Fisher\'s exact and McNemar\'s tests were used to compare proportions, and *t*-test and Wilcoxon test to compare continuous variables. Repeated measures were analyzed using generalizing estimating equations (GEE) models \[[@B10]\] with the first-order autoregressive correlation structure. The association between the likelihood of reporting a symptom and variables at initial classification (i.e., age at initial classification, sex, race, education, income, fatigue severity, wellness score, illness duration, onset type, and age at onset) was determined by using the binomial distribution with the logit link. Symptoms were grouped as CFS symptoms (those in the CFS case definition \[[@B1]\]) or non-CFS symptoms (those not included in the case definition). Models for the number of CFS or non-CFS symptoms used the normal distribution with the identity link. Logistic regression models were used to determine predictors of remission. All tests were 2-sided and p-values were considered significant if they did not exceed 0.05. All analyses were conducted using SAS version 8.1 (SAS Inc., Cary, NC).

Results
=======

Characteristics at initial CFS classification
---------------------------------------------

Among all fatigued subjects who came to the clinic over the study period, 90 were identified with CFS (43 of 300 in 1997, 15 of 270 in 1998, 22 of 291 in 1999, and 10 of 217 in 2000). Of these, 65 (72.2%) had at least one follow-up visit and thus were considered in this study. Tables [2](#T1){ref-type="table"},[3](#T2){ref-type="table"},[4](#T3){ref-type="table"},[5](#T4){ref-type="table"} describe these subjects\' characteristics at initial classification. More than three-quarters of our sample self-reported their onset as gradual and only 13.9% reported ever being diagnosed or treated for CFS (Table [3](#T2){ref-type="table"}). A diagnosis of depression was self-reported by 30.8% of the subjects, but only 16.9% had lifetime major depression disorder according to the DIS. The most prevalent CFS symptom was unrefreshing sleep and the most prevalent non-CFS symptom was problems getting to sleep (Table [4](#T3){ref-type="table"}). More than 60% were currently employed, and only 16.9% reported unemployment due to the fatiguing illness (Table [5](#T4){ref-type="table"}). Approximately 20% reported short duration of fatigue (≤ 2 years). Compared with published data for CFS subjects \[[@B9]\], our sample had a significantly higher mean for the situation-specific fatigue subscale (*t*-test p-value = 0.0087) and a significantly lower mean for the subscale indicating fatigue responsiveness to rest or sleep (*t*-test p-value = 0.0167).

###### 

Demographic characteristics of CFS subjects at initial classification (N = 65)

  Characteristic                                           Description
  -------------------------------------------------------- --------------------
  Female (%)                                               83.1
  Current age in years (mean, standard deviation, range)   46 (9, 27--69)
  Race (%)                                                 
   White                                                   89.2
   Black                                                   3.1
   American Indian                                         4.6
   Other                                                   3.1
  Hispanic origin (any race) (%)                           1.5
  Education beyond high school (%)                         63.1
  Household income in previous year (%)                    
   \<\$20,000                                              23.1
   \$20,001--\$40,000                                      23.1
   \>\$40,000                                              44.6
   Declined revealing                                      9.2
   Median                                                  \$30,000--\$40,000
  Current or most recent job (%)                           
   Professional                                            20.3
   Clerical work                                           20.3
   Sales worker or representative                          9.4
   Homemaker                                               9.4
   Owner/proprietor                                        9.4
   Technician                                              9.4
   Manager, official                                       7.8
   Other                                                   14.0
  Current living situation (%)                             
   Alone                                                   24.6
   Couple with/without children                            64.6
   Single parent/living with family, friends               10.8

###### 

Clinical characteristics of CFS subjects at initial classification (N = 65)

  Characteristic                                            Description
  --------------------------------------------------------- --------------------
  Age at onset (mean, standard deviation, range) in years   37.1 (11.0, 5--57)
  Median proportion of life with illness\*                  13.0
  Self reported onset type (%)                              
   Gradual                                                  76.9
   Sudden                                                   20.0
   Don\'t know/declined reply                               3.1
  Body mass index (%)                                       
   20--24: Normal                                           26.2
   25--29: Overweight                                       33.8
   ≥ 30:Obese                                               40.0
   Median (interquartile range)                             27 (24--31)
  Ever been diagnosed or treated by a physician (%)         
   Fibrositis or fibromyalgia                               32.3
   Depression                                               30.8
   Allergies confirmed by formal testing                    21.5
   Irritable bowel syndrome                                 18.5
   Temporomandibular joint syndrome                         16.9
   CFS                                                      13.9
   Environmental sensitivity disease                        1.5
   Yeast infection (only females)                           48.2
  Diagnostic Interview Schedule (%)                         
   Current/Lifetime somatization                            0
   Lifetime major depression disorder                       16.9

\* Ratio between illness duration (in years) and age (in years)

###### 

Symptoms and wellness scores for CFS subjects at initial classification and follow-up

  Characteristic                                                 Initial classification (N = 65)   1-year follow-up (N = 59)   2-years follow-up (N = 39)   3-years follow-up (N = 24)
  -------------------------------------------------------------- --------------------------------- --------------------------- ---------------------------- ----------------------------
  CFS symptoms lasting ≥ 6 months (%)                                                                                                                       
   Unrefreshing sleep                                            95.4                              88.1                        89.7                         79.2\*
   Muscle aches or muscle pain                                   92.3                              74.6\*                      74.4\*                       66.7\*
   Unusual fatigue post-exertion                                 78.5                              50.9\*                      53.9\*                       33.3\*
   Difficulty thinking/concentrating or memory problems          76.9                              71.2                        59.0                         62.5
   Pain in joints                                                73.9                              64.4                        64.1                         66.7
   Severe headaches                                              58.5                              35.6\*                      41.0                         29.2\*
   Tender lymph nodes                                            16.9                              20.3                        12.8                         4.2
   Sore throat                                                   12.3                              6.8                         5.3                          0.0
  Number of CFS symptoms (%)                                                                                                                                
   0                                                             0.0                               1.7                         7.7                          4.2
   1--3                                                          0.0                               32.2                        25.6                         50.0
   7--8                                                          7.7                               10.2                        2.6                          0.0
   Mean number (standard deviation)                              5 (1.1)                           4.1 (1.7)\*                 4.0 (1.7)\*                  3.4 (1.5)\*
  Non-CFS symptoms lasting ≥ 6 months (%)‡                                                                                                                  
   Problems getting to sleep or waking up early in the morning   81.4                              69.5                        74.4                         75.0
   General weakness                                              80.0                              61.0\*                      74.4                         50.0\*
   Sinus or nasal problems                                       67.7                              50.9\*                      53.9                         58.3
   Sensitivity to light                                          56.9                              52.5                        59.0                         58.3
   Depression                                                    49.2                              44.1                        38.5                         37.5
   Numbness or tingling                                          35.9                              44.8                        30.8                         58.3\*
   Shortness of breath                                           35.4                              27.1                        23.1                         45.8
   Stomach or abdominal pain                                     24.6                              30.5                        28.2                         13.0
   Diarrhea                                                      20.0                              20.3                        20.5                         4.2
   Chills                                                        18.8                              13.6                        5.1                          4.2
   Nausea                                                        12.3                              6.8                         5.1                          4.2
   Fever                                                         12.3                              6.8                         0.0                          0.0
   Mean number (standard deviation)                              4.9 (2.0)                         4.3 (2.2)\*                 4.1 (2.1)                    4.1 (1.9)
  Total CFS and non-CFS symptoms, mean (standard deviation)      10 (2.5)                          8.4 (3.5)\*                 8.1 (3.5)\*                  7.5 (2.9)\*
  Wellness scores, mean (standard deviation)                     41.2 (17.3)                       48.5 (20.7)†                46.8 (20.5)                  50.4 (17.6)

\*p \< 0.05 in GEE models compared with values at T0 † p \< 0.05 in paired t-test ‡ Symptoms not included in CFS Case Definition

###### 

Illness characteristics among CFS subjects at initial classification and among fatigued subjects at follow-up

  Characteristic                                                       Initial classification (N = 65)   1-year follow-up (N = 49)   2-years follow-up (N = 29)   3-years follow-up (N = 18)
  -------------------------------------------------------------------- --------------------------------- --------------------------- ---------------------------- ----------------------------
  Fatigue duration in years (%)                                                                                                                                   
   \#2                                                                 18.5                              2.0                         0.0                          0.0
   2.1--5                                                              23.1                              20.4                        27.6                         11.1
   5.1--10                                                             30.8                              34.7                        31.0                         44.4
   \>10                                                                27.7                              42.9                        41.4                         44.4
   Median (interquartile range)                                        6 (3.6--10.8)                     7.5 (5.3--13.2)             8.0 (4.8--12.9)              9.4 (7.2--13.9)
  Rest did not relieve fatigue a lot (%)                               100                               95.2                        96.6                         94.4
  Since fatiguing illness began, it interfered a lot with (%)                                                                                                     
   Social activities                                                   76.9                              51.0\*                      62.1                         44.4
   Personal activities                                                 76.9                              69.4                        58.6                         55.6
   Work activities                                                     66.2                              42.9\*                      55.2                         33.3
   Educational activities                                              40                                28.6\*                      27.6                         27.8
   Median number of activities affected by fatigue                     3                                 2†                          3                            1.5
  Currently employed (%)                                               63.1                              61.2                        55.2                         55.6
  Unemployed because of fatiguing illness (%)                          16.9                              18.4                        13.8                         16.7
  Fatigue Assessment Instrument subscales, mean (standard deviation)                                                                                              
   Severity                                                            5.9 (0.9)                         5.6 (0.8) †                 5.8 (0.8)                    5.4 (1.0)
   Situation Specific                                                  4.3 (1.3) ‡                       4.3 (1.5)                   4.5 (1.4)                    3.8 (1.4)
   Psychological consequences                                          6.0 (1.0)                         6.0 (1.1)                   6.2 (0.7)                    5.8 (0.9)
   Responds to rest/sleep                                              3.8 (1.8) ‡                       3.3 (1.7)                   3.8 (2.0)                    3.4 (1.9)

\* p \< 0.05 in McNemar\'s test † p \< 0.01 in paired t-test ‡ p \< 0.05 in t-test, compared with published data

Follow-up visits
----------------

Of the 65 CFS subjects, 59 (90.8%), 39 (60%), and 24 (36.9%) were followed 1, 2, and 3 years, respectively, after initial classification. Reasons for missing visits included permanent exclusions in the previous visit, refusal to participate, cancellation of clinic appointment, or loss to follow-up (respondent moved or could not be located). Subjects with follow-up visits had shorter duration of illness (median = 6 years vs. 9.1 years, Wilcoxon test p-value = 0.0378), fewer non-CFS symptoms (mean = 4.9 vs. 6.2, *t*-test p-value = 0.0419) and higher annual income (49.2% vs. 20% above \$40,000, χ^2^test p-value = 0.0128) than those who were not followed. No differences were found with respect to age, sex, race, education, fatigue severity scores, wellness scores, or number of CFS symptoms.

Symptoms
--------

Using GEE models, it was determined that the mean number of CFS and non-CFS symptoms decreased over time compared with the number of symptoms at initial classification (Table [4](#T3){ref-type="table"}). Although the prevalence of CFS symptoms also tended to decrease over time, the ranking of symptoms remained the same. At all time points, unrefreshing sleep, muscle pain, post-exertion fatigue, difficulty thinking or memory impairment, and joint pain were the 5 most prevalent symptoms; whereas headaches, tender lymph nodes, and sore throat were the least prevalent symptoms.

Wellness, activities and sleep
------------------------------

Pairwise comparisons between consecutive time periods indicated that wellness scores were higher at the first year compared with initial evaluation (paired t-test p-value = 0.0085) (Table [4](#T3){ref-type="table"}). No other significant differences were detected.

At initial classification, the median number (interquartile range) of hours spent on work duties, household chores, recreational activities, and sleeping during the week and during the weekend was, respectively, 40 (15--60), 15 (7--20), 0 (0--5.5), 7 (6--8) and 8 (6--9). No significant changes over time were detected.

Fatigue characteristics
-----------------------

Only a few fatigued subjects reported that rest relieved fatigue at any follow-up period (Table [5](#T4){ref-type="table"}). The proportion of subjects reporting that fatigue interfered with social, professional, or educational activities at 1-year follow-up was significantly smaller than at initial classification (McNemar\'s test p-values = 0.002, 0.0124, 0.0290, respectively). Fatigue severity scores and number of activities affected by fatigue were also significantly reduced at 1-year follow-up (paired t-test p-values = 0.0047, 0.0001, respectively). No other significant differences were detected.

Illness states over time
------------------------

About one-third of CFS subjects retained the classification after 1 year of follow-up (Table [6](#T5){ref-type="table"}). At 2 and 3 years follow-up, only 21% of the subjects were classified as having CFS. Most transitioned into a non-CFS state because of insufficient symptoms or fatigue severity, absence of fatigue, or identification of an exclusionary condition. Overall, 23.1% (15 of 65) were eventually diagnosed with permanent exclusions, of which the most common were sleep disorders (i.e. sleep apnea or narcolepsy) (3 of 15), major depressive disorder with melancholia (3 of 15) and inflammatory bowel disease (2 of 15). Female sex, income ≤ \$40,000, older age at initial classification, and higher fatigue severity scores were positively associated with the eventual detection of an exclusionary condition (Fisher\'s exact test p-values = 0.0197, 0.0169, and *t*-test p-values = 0.0008, 0.0042, respectively). No deaths were observed in this study.

###### 

Changes in CFS classification (%)

  Classification                              1-year follow-up (N = 59)   2-years follow-up (N = 39)   3-years follow-up (N = 24)
  ------------------------------------------- --------------------------- ---------------------------- ----------------------------
  CFS                                         32.2                        20.5                         20.8
  Insufficient symptoms or fatigue severity   30.5                        30.8                         37.5
  Not fatigued                                15.3                        18.0                         20.8
  Exclusionary conditions                                                                              
   Permanent medical or psychiatric\*         8.5                         15.4                         16.7
   Temporary medical†                         13.6                        15.4                         4.2

\*Permanent exclusions include bulimia, bipolar disease, chronic hepatitis, body mass index = 47, Sjögren\'s syndrome, diabetes with complications, multiple sclerosis, inflammatory bowel disease (2 subjects), sleep apnea or narcolepsy (3 subjects) and major depressive disorder with melancholia (3 subjects) † Temporary exclusions include abnormal urinalysis, beta-blocker medication, results for positive Romberg\'s test, rheumatoid factor, abnormal liver function, hypertension, breast mass, multiple myeloma, and thyroid disease.

Table [7](#T6){ref-type="table"} illustrates the pattern of illness states over the 3-year follow-up period. Overall, 56.9% of the subjects (37 of 65) experienced partial or total remission by the end of the follow-up. Among 40 subjects who had 2 consecutive years of follow-up, 22.5% sustained partial remission and 10% sustained total remission. The 4 CFS subjects who sustained total remission had been ill between 0.7 and 19.8 years and ranged in age from 35 to 53 years. There were 3 individuals with gradual and 1 with sudden onset, 2 females, 3 whites, and 1 Hispanic. Only 3 (7.5%) of 40 subjects sustained the CFS classification over two consecutive follow-up visits.

###### 

Illness states for CFS subjects at follow-up

  No. of subjects        1-year follow-up (N = 59)   2-years follow-up (N = 39)   3-years follow-up (N = 24)
  ---------------------- --------------------------- ---------------------------- ----------------------------
  10                     CFS                         No visit                     No visit
  1                      CFS                         No visit                     CFS
  1                      CFS                         CFS                          No visit
  2                      CFS                         Partial Remission            No visit
  1                      CFS                         Partial Remission            No visit
  1                      CFS                         Partial Remission            CFS
  1                      CFS                         Temporary exclusion          Partial Remission
  1                      CFS                         Permanent exclusion          \-
  1                      CFS                         Permanent exclusion          \-
  3                      Partial Remission           No visit                     No visit
  3                      Partial Remission           CFS                          No visit
  1                      Partial Remission           CFS                          CFS
  1                      Partial Remission           CFS                          Partial Remission
  1                      Partial Remission           CFS                          Temporary exclusion
  2                      Partial Remission           Partial Remission            No visit
  1                      Partial Remission           Partial Remission            CFS
  2                      Partial Remission           Partial Remission            Partial Remission
  1                      Partial Remission           Partial Remission            Partial Remission
  1                      Partial Remission           Partial Remission            Permanent exclusion
  2                      Partial Remission           Temporary exclusion          Partial Remission
  1                      Partial Remission           Temporary exclusion          Permanent exclusion
  3                      Partial Remission           Total Remission              Total Remission
  1                      Total Remission             No visit                     Partial Remission
  1                      Total Remission             Permanent exclusion          \-
  2                      Total Remission             Permanent exclusion          \-
  1                      Total Remission             Total Remission              No visit
  5                      Temporary exclusion         No visit                     No visit
  1                      Temporary exclusion         Partial Remission            No visit
  1                      Temporary exclusion         Temporary exclusion          No visit
  1                      Temporary exclusion         Temporary exclusion          Partial Remission
  3                      Permanent exclusion         \-                           \-
  1                      Permanent exclusion         \-                           \-
  1                      Permanent exclusion         \-                           \-
  1                      No visit                    No visit                     Permanent exclusion
  1                      No visit                    CFS                          CFS
  1                      No visit                    Partial Remission            Partial Remission
  1                      No visit                    Partial Remission            Partial Remission
  1                      No visit                    Partial Remission            Permanent exclusion
  1                      No visit                    Permanent exclusion          \-
                                                                                  
  \% Partial remission   37.3                        38.5                         45.8
  \% Total remission     8.5                         10.3                         12.5

Reduced fatigue between visits and treatments used
--------------------------------------------------

Thirty-two (54.2%) of 59, 23 (59%) of 39 and 11 (45.8%) of 24 subjects followed at 1, 2, and 3 years, respectively, reported that they felt less fatigued since the last visit. More than half of the subjects reporting reduced fatigued experienced at least 6 periods (53.1%, 65.2%, and 63.6% at 1, 2, and 3 years, respectively) of reduced fatigue. The median duration of the most recent period was 8 days for years 1 and 2, and 30 days for year 3 of follow-up. Fatigue reduction was not significantly associated with remission at the follow-up visit.

Although traditional medicine was the most common treatment among subjects reporting reduced fatigue (100%, 91.7%, and 81.8% at 1, 2, and 3 years, respectively, Table [8](#T7){ref-type="table"}), only 20% reported using it exclusively. Most subjects reported a combination of traditional medicine, self-help strategies, and complementary and alternative medicine therapies (84.4%, 73.9%, and 63.6% at 1, 2, and 3 years, respectively). More than 35% of the subjects reported use of any complementary and alternative medicine at any point in time and at least 50% of those who used it thought that it reduced their fatigue (Table [8](#T7){ref-type="table"}). Remission was not associated with any particular treatment.

###### 

Treatment use and perception that the treatment was responsible for reduced fatigue at follow-up

  Treatment                                            \% reporting treatment use among subjects reporting reduced fatigue\*   \% believing treatment responsible for reduced fatigue among subjects reporting use                                
  ---------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------- --------- -------- --------- ---------
                                                       1-year                                                                  2-years                                                                               3-years   1-year   2-years   3-years
  Any traditional medicine                             100.0                                                                   91.7                                                                                  81.8      84.4     54.6      77.8
   Medical doctor, emergency room                      71.9                                                                    73.9                                                                                  63.6      34.8     23.5      57.1
   Prescription medication                             78.1                                                                    69.6                                                                                  63.6      64.0     37.5      71.4
   Over-the-counter medication                         65.6                                                                    65.2                                                                                  27.3      42.9     26.7      100.0
   Psychotherapy, counseling                           12.5                                                                    13.0                                                                                  9.1       50.0     33.3      100.0
   Vitamins                                            81.3                                                                    69.6                                                                                  72.7      65.4     56.3      62.5
  Any self-help strategy                               78.1                                                                    73.9                                                                                  54.6      68.0     41.2      83.3
   Exercise                                            68.8                                                                    65.2                                                                                  54.6      63.6     33.3      83.3
   Changes in diet                                     53.1                                                                    34.8                                                                                  27.3      58.8     50.0      66.7
  Any complementary and alternative medicine therapy   37.5                                                                    39.1                                                                                  36.4      50.0     77.8      100.0
   Herbal remedies                                     34.4                                                                    30.4                                                                                  27.3      45.5     71.4      100.0
   Homeopathy                                          6.3                                                                     4.4                                                                                   18.2      100.0    100.0     100.0
   Behavior modification (biofeedback)                 3.1                                                                     4.4                                                                                   0.0       0.0      100.0     0.0
   Acupuncture                                         15.6                                                                    4.4                                                                                   18.2      60.0     0.0       50.0

\* N = 32, 23, and 11 at 1, 2, and 3 years, respectively

Predictors of remission and symptom changes
-------------------------------------------

To determine predictors of remission and symptoms, we considered only the 50 subjects who never developed a permanent exclusion. Sixty-two percent of these subjects ever experienced a partial or total remission. There was no association between the report of ever being diagnosed or treated for CFS and remission (Fisher\'s exact test p-value = 1.0). Higher fatigue severity scores and larger total number of symptoms were negatively associated with ever experiencing remission. Odds ratios (OR) and 95% confidence intervals (CI) from a multivariate logistic regression model were, respectively, 0.389 (0.156--0.971) and 0.724 (0.533--0.985). Subjects who eventually remitted tended to have fewer symptoms at initial classification but this trend was not statistically significant. Among the 32 subjects with at least two visits, 25% sustained partial remission and 12.5% total remission. By using categories of illness duration of ≤ 2 years, 2.1--10 years, and \>10 years, it was found that subjects ill for 2.1--10 years were less likely to sustain remission than subjects ill for ≤ 2 years (OR = 0.107, 95% CI = 0.013--0.88). Subjects ill for \>10 years were also less likely to sustain remission than those with shorter duration of illness, but this trend was not statistically significant (OR = 0.625, 95% CI = 0.073--5.350). No other variables were associated with sustained remission.

Few variables at initial classification were univariately associated with the likelihood of reporting individual symptoms (data available from the authors). Unrefreshing sleep was associated with female sex, being white, having higher fatigue severity scores, and being ill for 2.1--10 years when compared with 2 years or less. In a multivariate GEE model for unrefreshing sleep including these variables, being white, fatigue severity, and illness duration remained significant (p-values = 0.0005, 0.0003, 0.0058, respectively). The number of CFS symptoms was positively associated with higher fatigue severity scores (p-value = 0.0043), but the number of non-CFS symptoms was not associated with any variable.

Discussion
==========

Our data revealed a complex and intermittent pattern of illness over time, where persistent CFS was the exception and not the rule. We found that 20%-33% of the originally identified CFS subjects remained in the CFS state at any subsequent visit, and only 7.5% remained in the CFS state for two consecutive periods. Although 56.9% experienced remission at some point during follow-up, only 22.5% sustained partial and 10% sustained total remission for two consecutive periods. We believe the apparent discrepancy between the low proportion of subjects who consistently fulfilled CFS criteria over time and the similarly low proportion that sustained total remission may reflect characteristics of the study design. Persons were classified as CFS only if they satisfied all criteria at the time of their clinical evaluation. Thus, individuals who met criteria shortly before evaluation but had temporarily improved around the time of their appointment (i.e., reported insufficient symptoms or fatigue severity) were not classified as having CFS. Clinical diagnosis is probably less conservative and practitioners would have continued to endorse CFS in such persons over time.

Permanent exclusions were identified in 23.1% of the subjects by the end of follow-up. Sleep apnea or narcolepsy and major depression disorder with melancholia were the most prevalent (20%). This proportion was remarkably higher than clinic-based studies that report rates between 2% and 13% \[[@B2]\]. This discrepancy may be due to the different case ascertainment approaches in clinical and population-based settings. Clinic-based studies reflect subjects seen at referral clinics who have generally been triaged and well evaluated to rule out known exclusionary conditions. In contrast, persons in our study represented the occurrence of the illness in the Wichita population. Since only 13.9% had ever been treated or diagnosed with CFS, the majority had either not perceived their status as an illness or had not undergone evaluation for identifiable causes of fatigue. Thus, it is not surprising that by yearly examination of our participants, we identified a high proportion of medical or psychiatric exclusions. In any event, this highlights the importance of health care providers consistently following their patients over time so that diseases can be promptly recognized and treated.

Most studies that describe the clinical course of CFS are set in hospitals or specialty clinics and include chronically ill patients. These subjects usually experience a poor outcome. Some investigators have suggested that subjects from primary care clinics or the general population might have better prognosis \[[@B11]\]. Contrary to these expectations, our population-based remission rates were within the range of those published in the literature of clinical studies \[[@B2]-[@B6]\]. Illness duration was the only predictor of sustained remission and this effect could be detected only when we defined categories of duration. Subjects with shorter duration of illness (≤ 2 years) were more likely to sustain remission than subjects ill for a longer time. It thus seems important to consider the possibility that the effect on clinical course outcomes is not the same for each additional illness duration year. Failure to define clinically meaningful categories may explain inconsistent associations across studies. Finally, in agreement with other studies \[[@B2]\], no deaths occurred in our sample.

We found a steady decrease in the number of CFS symptoms over time. However, unrefreshing sleep, the most common and persistent symptom at all follow-up periods, was still reported by 79.2% of subjects at the end of follow-up. Unrefreshing sleep was also one of the most commonly reported symptoms (87.5%) in another population-based study \[[@B12]\]. Of interest, subjects reported sleeping a median of 7 hours on weekdays. Thus, although hours of sleep were within normal limits, subjects found their sleep non-restorative. This observation has also been noted in a study of sleep, using polysomnography, in CFS patients who slept an average of 7 hours per night but reported feeling unrefreshed on waking \[[@B13]\].

We found decreased fatigue severity scores at the 1-year follow-up, but these levels were still significantly higher than values for normal fatigued controls \[[@B9]\]; thus, from a practical standpoint, subjects remained severely fatigue throughout the follow-up period. Despite this observation, our sample was highly functional (e.g., approximately 60% remained currently employed and worked a median of 40 hours per week) compared with other samples in published literature \[[@B3]-[@B6]\].

There is currently no standard treatment for CFS. A recent systematic review \[[@B14]\] concluded that cognitive behaviour therapy and graded exercise therapy have shown promising results in controlled trials that evaluated interventions in CFS subjects. These therapies, however, are not widely available to the general public. Although there is insufficient evidence that complementary and alternative medicine therapies are effective \[[@B14]\], they are definitely more accessible. In our study, almost 100% of our subjects who felt less fatigued between clinic visits used traditional medicine treatments, but more than 35% reported use of complementary and alternative medicine therapies, such as herbal remedies, homeopathy, biofeedback, and acupuncture. This figure is twice as high as the 1997 US national prevalence estimate of 17.5% \[[@B15]\]. These therapies might be more prevalent among CFS subjects than the general population because of patients\' desire to improve their health status and their lack of success with traditional approaches.

Our findings are limited by reduced sample size over time, which was due to elimination of subjects with permanent exclusionary conditions, refusals, or loss to follow-up. These factors should be considered when estimating the size of future longitudinal studies. In addition, we did not have a standardized measure of improvement or recovery, nor did we ask subjects whether they considered themselves partially or fully recovered. We created a definition based on absence of CFS case-defining criteria. This definition did not assess any measurable change in physical or mental function that could objectively indicate meaningful recovery from a clinical standpoint. As with so many other CFS parameters, it is fundamental that standardized measures of recovery be developed so that ambiguities in the clinical course of CFS are resolved. Last, most of our subjects reported a gradual onset and long duration of illness. Given enough subjects with sudden onset and/or short duration of illness, prognosis might have been quite different.
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